ANG Lifesciences India Limited has formally responded to BSE Limited's inquiry regarding unusual price movement in its securities, clarifying that no undisclosed price-sensitive information exists that could explain the recent market activity.

BSE Inquiry and Company Response

The pharmaceutical company issued its clarification on April 10, 2026, in response to BSE's email dated April 09, 2026. The exchange had sought an explanation for the recent price and volume behavior of the company's securities under BSE Security Code 540694.

Company's Official Position

In its formal communication signed by Managing Director Rajesh Gupta, ANG Lifesciences stated that there is no additional information or announcement that is price-sensitive under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which could have influenced the security's price or volume behavior.

The company emphasized several key points in its clarification:

• No undisclosed price-sensitive information exists
• Price movement is purely market-driven
• The company has no control or knowledge of market-driven price movements
• Regular compliance with SEBI disclosure requirements is maintained

Regulatory Compliance Statement

ANG Lifesciences reaffirmed its commitment to regulatory compliance, stating that it has been regularly disseminating price-sensitive information and making required disclosures from time to time in accordance with SEBI regulations. The company's response demonstrates adherence to transparency requirements while clarifying that recent market activity cannot be attributed to any corporate developments or undisclosed information.

The clarification serves to address market speculation and provides assurance to investors and regulators that the company maintains proper disclosure practices in line with listing obligations.

ANG Lifesciences India Limited has announced its unaudited financial results for the quarter and nine months ended December 31, 2025, following Board approval on February 14, 2026. The company reported comprehensive standalone and consolidated results prepared in accordance with SEBI regulations.

Financial Performance Overview

The company's standalone financial results for Q3 FY26 showed mixed performance across key metrics. Revenue from operations and other comprehensive financial data were disclosed as part of the quarterly reporting cycle.

Segment-wise Performance

The consolidated results reflect the company's two primary business segments. The pharmaceuticals segment and printing & packaging segment through subsidiary Mansa Print & Publishers Limited showed varied performance patterns.

Board Meeting and Regulatory Compliance

The Board of Directors convened on Saturday, February 14, 2026, to consider and approve the standalone and consolidated unaudited financial results. The meeting commenced at 05:00 PM and concluded at 07:20 PM. The results were prepared pursuant to Regulation 30 & 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Auditor Review and Business Operations

The company's statutory auditors, M/s Khurana Sharma & Co., Chartered Accountants, issued a limited review report on the unaudited financial results. The review was conducted in accordance with Standard on Review Engagements (SRE) 2410. ANG Lifesciences operates as a pharmaceutical manufacturing company with products including Liquid Injections, Vials, Ampoules, Hard Gelatin capsules, and various therapeutic formulations covering Antibiotics, Antiviral, Antimalarial, and other major categories.

The financial results are available on the company's website at www.anglifesciences.com and on the Bombay Stock Exchange website at www.bseindia.com .